Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings & Alex G. Ortega-Loayza. (2019) Biologic and small-molecule medications in the management of pyoderma gangrenosum. Journal of Dermatological Treatment 30:3, pages 264-276.
Read now
Read now
Articles from other publishers (34)
Aleksandra Opalińska, Dominika Kwiatkowska, Adrian Burdacki, Mirosław Markiewicz, Dominik Samotij, Marek Dudziński, Jadwiga Niemiec-Dudek, Elżbieta Ostańska & Adam Reich. (2021) Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature. Dermatology and Therapy 11:4, pages 1217-1237.
Crossref
Crossref
Jacquelyn Majerowski & Kenneth B. Gordon. 2021. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy
287
301.e7
.
Emanual Maverakis, Angelo V. Marzano, Stephanie T. Le, Jeffrey P. Callen, Marie-Charlotte Brüggen, Emmanuella Guenova, Joachim Dissemond, Kanade Shinkai & Sinéad M. Langan. (2020) Pyoderma gangrenosum. Nature Reviews Disease Primers 6:1.
Crossref
Crossref
Quoc-Bao D. Nguyen, Caroline T. Starling & Adelaide A. Hebert. (2020) The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders. Pediatric Drugs 22:3, pages 311-319.
Crossref
Crossref
Hakim Ben Abdallah, Karsten Fogh & Rikke Bech. (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review. International Wound Journal 16:2, pages 511-521.
Crossref
Crossref
Benedetta Terziroli Beretta-Piccoli, Pietro Invernizzi, M. Eric Gershwin & Carlo Mainetti. (2017) Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clinical Reviews in Allergy & Immunology 53:3, pages 394-412.
Crossref
Crossref
Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard & Robert S. Kirsner. (2017) Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology 18:3, pages 355-372.
Crossref
Crossref
Anthony D. Ormerod & Philip J. Hampton. 2016. Rook's Textbook of Dermatology, Ninth Edition. Rook's Textbook of Dermatology, Ninth Edition
1
23
.
Theodoros Androutsakos, Paraskevas Stamopoulos, Kiriaki Aroni & Gregorios Hatzis. (2015) A case report of successful treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis, and review of the literature. BMC Gastroenterology 15:1.
Crossref
Crossref
Heidi Wat & Richard M. Haber. (2014) Trends in the Association between Pyoderma Gangrenosum and Autoimmune Hepatitis: Case Report and Review of the Literature. Journal of Cutaneous Medicine and Surgery 18:5, pages 345-352.
Crossref
Crossref
Agustin Castiella. (2014) Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World Journal of Hepatology 6:4, pages 160.
Crossref
Crossref
Michael A Heneghan, Andrew D Yeoman, Sumita Verma, Alastair D Smith & Maria Serena Longhi. (2013) Autoimmune hepatitis. The Lancet 382:9902, pages 1433-1444.
Crossref
Crossref
Palak J. Trivedi & Gideon M. Hirschfield. (2013) Treatment of autoimmune liver disease: current and future therapeutic options. Therapeutic Advances in Chronic Disease 4:3, pages 119-141.
Crossref
Crossref
Stephanie Mehlis & Kenneth B. Gordon. 2013. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy
307
318.e4
.
Kawtar Beqqal, Mariame Meziane, Boutaina Khatibi, Yasmine Ouidan, Karima Senouci, Leila Benzekri, Badreddine Hassam & Fatima Zohra Belgnaoui. (2012) Nodules ulc?ro-bourgeonnants multiples. Annales de Pathologie 32:4, pages 284-286.
Crossref
Crossref
Vincent Falanga, Christina Lindholm, Polly A. Carson, Jaymie Panuncialman, Lisa Mamakos, Tiziana N. Lotti & Jane K. Falanga. 2012. Text Atlas of Wound Management. Text Atlas of Wound Management
207
218
.
Jaymie Panuncialman & Vincent Falanga. (2010) Unusual Causes of Cutaneous Ulceration. Surgical Clinics of North America 90:6, pages 1161-1180.
Crossref
Crossref
A. D. Yeoman & M. A. Heneghan. (2010) Anti TNF‐α therapy can be a novel treatment option in patients with autoimmune hepatitis: authors’ reply. Alimentary Pharmacology & Therapeutics 32:1, pages 116-117.
Crossref
Crossref
Joni Mazza, Anthony Rossi & Jeffrey M. Weinberg. (2010) Innovative Uses of Tumor Necrosis Factor α Inhibitors. Dermatologic Clinics 28:3, pages 559-575.
Crossref
Crossref
Robert S. Kirsner. (2010) Biological Agents for Chronic Wounds. American Journal of Clinical Dermatology 11, pages 23-25.
Crossref
Crossref
Ye H. Oo, Stefan G. Hubscher & David H. Adams. (2010) Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatology International 4:2, pages 475-493.
Crossref
Crossref
J.M. Hernanz. (2010) Etanercept. Otras indicaciones. Actas Dermo-Sifiliográficas 101, pages 111-116.
Crossref
Crossref
A. D. YEOMAN, M. S. LONGHI & M. A. HENEGHAN. (2010) Review article: the modern management of autoimmune hepatitis. Alimentary Pharmacology & Therapeutics 31:8, pages 771-787.
Crossref
Crossref
Jeremiah Miller, Brad A. Yentzer, Adele Clark, Joseph L. Jorizzo & Steven R. Feldman. (2010) Pyoderma gangrenosum: A review and update on new therapies. Journal of the American Academy of Dermatology 62:4, pages 646-654.
Crossref
Crossref
Ugur Halac, Rola Al Dhaybi, Julie Powell, Dorothée Bouron-Dal Soglio & Fernando Alvarez. (2010) Unusual Association Between Autoimmune Hepatitis and Severe Pyoderma Gangrenosum. Journal of Pediatric Gastroenterology & Nutrition 50:2, pages 219-221.
Crossref
Crossref
Tomer Adar, Meir Mizrahi, Orit Pappo, Anat Scheiman-Elazary & Oren Shibolet. (2010) Adalimumab-induced Autoimmune Hepatitis. Journal of Clinical Gastroenterology 44:1, pages e20-e22.
Crossref
Crossref
Heidemarie Becker, Peter Willeke, Wolfram Domschke & Markus Gaubitz. (2008) Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clinical Rheumatology 27:12, pages 1597-1598.
Crossref
Crossref
G. Guhl, B. Díaz-Ley & J. Fernández-Herrera. (2008) Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab. Actas Dermo-Sifiliográficas 99:1, pages 5-33.
Crossref
Crossref
G. Guhl, B. Díaz-Ley & J. Fernández-Herrera. (2008) Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab. Actas Dermo-Sifiliográficas (English Edition) 99:1, pages 5-33.
Crossref
Crossref
Alper Yurci, Kadri Guven, Edip Torun, Sebnem Gursoy, Mevlut Baskol, Hulya Akgun, Omer Ozbakir & Mehmet Yucesoy. (2007) Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. European Journal of Gastroenterology & Hepatology 19:9, pages 811-815.
Crossref
Crossref
Ziad Reguia??Florent Grange. (2007) The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease. American Journal of Clinical Dermatology 8:2, pages 67-77.
Crossref
Crossref
Julia E. Graves, Kara Nunley & Michael P. Heffernan. (2007) Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). Journal of the American Academy of Dermatology 56:1, pages e55-e79.
Crossref
Crossref
Martin Röcken & Christina Weigert. 2007. Fortschritte der praktischen Dermatologie und Venerologie 2006. Fortschritte der praktischen Dermatologie und Venerologie 2006
41
51
.
Mary Jo. J. Kerns, Julia E. Graves, David I. Smith & Michael P. Heffernan. (2006) Off-Label Uses of Biologic Agents in Dermatology: A 2006 Update. Seminars in Cutaneous Medicine and Surgery 25:4, pages 226-240.
Crossref
Crossref